Surrozen Corp (SRZN): Earnings per share for the last twelve months

Symbol and logo of brand Surrozen Inc (SRZN)

Risks for Surrozen, Inc. (SRZN) are linked to the early stage of clinical trials and the search for partners. However, high scientific potential in organ regeneration and the prospect of monopoly pricing power offset these concerns. This rolling annual EPS chart demonstrates a support level where the metric holds around -47.10, confirming the current earnings per share trend.

Surrozen, Inc. (SRZN) - Net earnings per share (EPS TTM) from 07/04/2022 to 11/15/2026

Analytical breakdowns for Surrozen Inc. (SRZN)

- current quotes and average value forecast:
Price Chart Surrozen Inc|SRZN - Analyst Median Target
- stock exchange capitalization data:
Market Value Surrozen|SRZN - Company Buyout Price
- shareholders' equity book value data:
Accounting Value per Share Surrozen|SRZN - Book Capitalization|Market Value to Book Value Ratio surrozen.com|SRZN - Aggregate Asset Value
- issuer credit burden and liquidity indicators:
Debt to Equity Surrozen, Inc.|SRZN - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Surrozen Inc|SRZN - Company Cumulative Debt|Debt to Book Value Surrozen Inc|SRZN - Long-Term Liabilities|Company Short-Term Debts Surrozen|Quick Liquidity surrozen.com
- earnings and valuation multiples indicators:
SRZN - Company Profit|Future Profit Surrozen, Inc.|SRZN - Company Value to Net Income|Forward P/E Multiple Surrozen Inc.|SRZN - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Surrozen|SRZN - Operating profit before amortization|Net earnings per share (EPS TTM) Surrozen|SRZN - Net earnings per share for the last 12 months|Year-over-year net earnings per share growth for the last 12 months surrozen.com|SRZN - Expected net earnings per share growth this year|Net earnings per share growth forecast for next year Surrozen, Inc.
- sales and revenue data:
SRZN - Company Gross Revenue|Company Projected Revenue Surrozen|SRZN - Market Capitalization-to-Revenue Ratio|Forward Price-to-Revenue Multiple Surrozen Inc|SRZN - Trailing Twelve Months Sales Growth
Basic company analysis:Surrozen, Inc. - SRZN
Mass-produced product of Surrozen Corp

Partner payments from pharmaceutical corporations for access to the Wnt modeling platform form the current financial basis of Surrozen, Inc. (SRZN). This metric is calculated as the total annual net income divided by the total number of shares. Investors use this indicator to assess the real return on each ownership stake. It allows for the separation of operational efficiency from the impact of share issuance. By analyzing the trailing 12-month earnings per share trend, the market compares actual cash flow with the potential of the clinical pipeline.

Key competitors

MESO - Earnings per share for the last twelve months|Net earnings per share for the last four quarters Lineage Cell Therapeutics Inc LCTX|CCEL: Net earnings per share (EPS TTM)|Earnings per one share for the last 12 months FBLG (FibroBiologics Inc.)|Earnings per share for the last twelve months Longeveron Inc|biorestorative.com (BRTX) - Net earnings per share for the last four quarters|Net earnings per share (EPS TTM) CELZ